Optimizing tacrolimus therapy in the maintenance of renal allografts: 12-month results

Transplantation

Volumn 86, Issue 1, 2008, Pages 88-95

  Bolin, Paul ^a   Shihab, Fuad S ^b   Mulloy, Laura ^c   Henning, Alice K ^d   Gao, Jeff ^d   Bartucci, Marilyn ^e   Holman, John ^e   First, M Roy ^e  

^a EAST CAROLINA UNIVERSITY   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d EMMES CORPORATION   (United States)

^e ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

1 year; Kidney transplantation; Optimizing; Tacrolimus

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CREATININE; CYCLOSPORIN A; CYSTATIN C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; LIPID;

ACUTE GRAFT REJECTION; ADULT; AGED; ALOPECIA; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FRACTURE; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERTROPHY; GRAFT REJECTION; GRAFT SURVIVAL; HEART DISEASE; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRICHOSIS; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; SURVIVAL RATE; BLOOD; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; DRUG EFFECT; KIDNEY FUNCTION TEST; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; QUALITY OF LIFE; RISK FACTOR; TIME; TREATMENT OUTCOME; UNITED STATES;

ADULT; CARDIOVASCULAR DISEASES; CYCLOSPORINE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; LIPIDS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; RISK FACTORS; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 49849086524     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31817442cf     Document Type: Article

References (22)

1. Olyaei AJ, de Mattos AM, Bennett WM. Nephrotoxicity of immuno-suppressive drugs: New insight and preventive strategies. Curr Opin Crit Care 2001; 7: 384.
2. Hariharan S, McBride MA, Cherikh WS, et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62: 311.
3. Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003; 75: 1291.
4. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715. [Erratum in: N Engl J Med 2005; 352: 1056].
5. Wong W, Venetz JP, Tolkoff-Rubin N, et al. 2005 immunosuppressive strategies in kidney transplantation: Which role for the calcineurin inhibitors? Transplantation 2005; 80: 289.
6. Abramowicz D, del Carmen Rial M, Vitko S, et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: Results of a five-year, prospective, randomized study. J Am Soc Nephrol 2005; 16: 2234.
7. Kasiske BL, Chakkera HA, Louis TA, et al. A meta-analysis of immu-nosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000; 11: 1910.
8. Flechner SM, Goldfarb D, Solez K, et al. Kidney Transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to cal-cineurin inhibitor drugs. Transplantation 2007; 83: 883.
9. Dudley C, Pohanka E, Riad H, et al. Mycophenolate mofetil substitution for cyclosporine A in renal transplant recipients with chronic progressive allograft dysfunction: The "creeping creatinine" study. Transplantation 2005; 79: 466.
10. Gallagher MP, Hall B, Craig J, et al. A randomized controlled trial of cyclosporine withdrawal in renal-transplant recipients: 15-year results. Transplantation 2004; 78: 1653.
11. Hernández D, Miquel R, Porrini E, et al. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression. Transplantation 2007; 84: 706.
12. Frimat L, Cassuto-Viguier E, Charpentier B, et al. Impact of cyclo-sporine reduction with MMF: A randomized trial in chronic allo-graft dysfunction. The 'reference' study. Am J Transplant 2006; 6: 2725.
13. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562.
14. Hathaway D, Winsett R, Prendergast M, et al. The first report from the patient outcomes registry for transplant effects on life (PORTEL): Differences in side-effects and quality of life by organ type, time since transplant and immunosuppressive regimens. Clin Transplant 2003; 17: 183.
15. Magera MJ, Lacey JM, Casetta B, et al. Method for the determination of total homocysteine in plasma and urine by stable isotope dilution and electrospray tandem mass spectrometry. Clin Chem 1999; 45: 1517.
16. 2006 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1996-2005. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD.
17. Vincenti F, Jensik SC, Filo RS, et al. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: Evidence for improved allograft survival at five years. Transplantation 2002; 73: 775.
18. Waid T for the CRAF Study Group. Tacrolimus as secondary intervention vs. cyclosporine continuation in patients at risk for chronic renal allograft failure. Clin Transplant 2005; 19: 573.
19. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: A meta-analysis. Am J Kidney Dis 2002; 40: 221.
20. McCune TR, Thacker LR II, Peters TG, et al. Effects of tacrolimus on hyperlipidemia after successful renal transplantation. Transplantation 1998; 65: 87.
21. Pirsch JD, Miller J, Deierhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997; 63: 977.
22. First MR, Gerber DA, Hariharan S, et al. Posttransplant diabetes mellitus in kidney allograft recipients: Incidence, risk factors, and management. Transplantation 2002; 73: 379.